Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors

Trial Profile

Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Gallium 68 satoreotide (Primary) ; Lutetium-177-DOTA-satoreotide (Primary)
  • Indications Carcinoid tumour; Gastric cancer; Lung cancer; Neuroendocrine tumours; Pancreatic cancer; Rectal cancer; Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jun 2017 New trial record
    • 06 Jun 2017 Results (n=19), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top